Related Posts

• Vertex on the Rise, Sirtris on TV, an IPO (Finally) on the Table, and More Life Sciences News
• Patent Reform Blocked, Epix Deal Expanded, Repligen Suit Settled, & More Life Sciences News
• Cancer Patient Can Use Newton Firm's Drug, FDA Says
• GTC Biotherapeutics, Racing Against Time to Prove the Worth of "Pharming"
• GTC Biotherapeutics Drug Passes Clinical Milestone, Helping Blaze the Trail for U.S. "Pharming"

Diganostics, FDA, clinicals

Repligen Launches Trial of Imaging Agent

Rebecca Zacks 3/26/08 12:22 pm

Repligen (NASDAQ: RGEN) of Waltham, MA, has begun a Phase 3 clinical trial of an imaging agent that would enhance the ability of magnetic resonance imaging (MRI) to detect abnormalities in the ducts of the pancreas, the company announced today. The company believes that the study, being conducted at about 30 U.S. and Canadian sites, could provide enough data to warrant approval of the agent, which is a synthetic version of the hormone secretin. The agent could potentially be used during some 150,000 pancreatic scans in the U.S. each year, according to Repligen.

Permalink | Share |

Why is this story so short? Because it's a news brief from our News Xpress section, which brings you quick takes on the latest Boston-area biz/tech news as it unfolds throughout the day.

Where do I find more in-depth news and analysis about the business of technology in the Boston area? We've got plenty of that right on our home page and in our archives.

Who the heck are the Xconomists mentioned on your homepage? They're an elite group of movers and shakers in the local tech scene who've generously agreed to share their insights and opinions with Xconomy's readers. Here's a complete list of them; to read their posts, have a look here and here.

Come to think of it, what does "Xconomy" mean in the first place? Xconomy is a word we made up to evoke the exponential economy—the realm of business and innovation characterized by exponential technological growth and responsible for an increasing share of productivity and overall economic growth. (Not everybody likes the name, by the way. We're okay with that.) We're a small group of professional journalists dedicated to bringing you the most important news about New England's role in the exponential economy. More on our mission and team here.